The patents-based pharmaceutical development process: rationale, problems, and potential reforms.

  title={The patents-based pharmaceutical development process: rationale, problems, and potential reforms.},
  author={John H. Barton and Ezekiel J. Emanuel},
  volume={294 16},
The pharmaceutical industry is facing substantial criticism from many directions, including financial barriers to access to drugs in both developed and developing countries, high profits, spending on advertising and marketing, and other issues. Underlying these criticisms are fundamental questions about the value of the current patent-based drug development system. Six major problems with the patent system are (1) recovery of research costs by patent monopoly reduces access to drugs; (2) market… Expand
Value of pharmaceuticals: ensuring the future of research and development.
A royalty-based system for the marketing of generic products after the expiration of initial patents has the potential to promote innovation, provide for more thorough clinical studies, reduce prices, and share know-how. Expand
How Efficient is the Patent System? A General Appraisal and an Application to the Pharmaceutical Sector
In recent years, the legal protection of intellectual property through patents has faced substantial criticism from several quarters. Patents have been questioned regarding the material scope ofExpand
DD No . 18 / 04 FreeRiding in Pharmaceutical Price Regulation : Theory and Evidence
We present a model of the strategic interaction among authorities regulating pharmaceutical prices in different countries and the R&D investment decisions of pharmaceutical firms. Regulators’Expand
Australian Pharmaceutical Policy: Price Control, Equity, and Drug Innovation in Australia
Should drug innovation come to dominate Australian pharmaceutical policy, there is the potential to precipitate a devaluing of the current public orientation of regulation and diminish equitable access to affordable pharmaceuticals. Expand
A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness.
It is demonstrated that a general arbitrary threshold may prevent further efficient R&D and disease-specific characteristics are an additional consideration in CE decision rules to accommodate the particularities of innovation across disease areas. Expand
Late-stage pharmaceutical R&D and pricing policies under two-stage regulation.
A model combining the two regulatory stages relevant to the approval of a new health technology: the authorisation of its commercialisation and the insurer's decision about whether to reimburse its cost shows that there exists a range of values of the uncertainty parameter over which a reduction in uncertainty benefits the firm, the insurer and patients. Expand
Access to medicines, market failure and market intervention: A tale of two regimes
It is argued that a parallel ‘pro-access regime’ has developed in order to correct some of the most high-profile issues associated with a dysfunctional global pharmaceutical market, especially problems regarding price and innovation that have been exacerbated by stringent global patent rights on new drugs. Expand
Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.
According to this comparative analysis, a first sensible step might be to classify active ingredients as those addressing neglected pathologies and those for diseases that are already successfully treated, thus offering more limited therapeutic gains by definition. Expand
The history and economics of pharmaceutical patents
The relationship between patents and the pharmaceutical industry is both complex and important. While many believe that patents are manipulated by the pharmaceutical industry for its own economicExpand
Demythologizing the high costs of pharmaceutical research
It is widely claimed that research to discover and develop new pharmaceuticals entails high costs and high risks. High research and development (R&D) costs influence many decisions and policyExpand


Post‐TRIPS Options for Access to Patented Medicines in Developing Nations
This article explores the tension between granting patent protection under the TRIPS Agreements and the availability of medicines at affordable prices to developing countries. A crucial considerationExpand
TRIPS and the global pharmaceutical market.
  • J. Barton
  • Medicine, Economics
  • Health affairs
  • 2004
The international controversy over patents and access to drugs in developing countries is reviewed and the implications of the 1995 Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, the 2001 Doha Declaration, and the 2003 agreement preceding the Cancun meeting are explored. Expand
The price of innovation: new estimates of drug development costs.
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drugExpand
The changing structure of the pharmaceutical industry.
The creation of a market for biomedical science and increased vertical competition within the industry are likely to spur innovation and raise productivity, but they also could induce socially wasteful spending and weaken academic science. Expand
The pharmaceutical industry--prices and progress.
  • F. Scherer
  • Medicine
  • The New England journal of medicine
  • 2004
The author discusses the policy dilemmas resulting from the complex economics of pharmaceutical research and development and reviews potential strategies to control prices. Expand
Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
The Orphan Drug Act provides public subsidies and incentives to spur the development of drugs for rare diseases--drugs that the private sector might otherwise consider unprofitable to produce.Expand
Patent Buy-Outs: A Mechanism for Encouraging Innovation
In 1839, the French government purchased the patent on the Daguerreotype process and" placed it in the public domain. This paper examines a mechanism under which governments" would use an auction toExpand
The safety of newly approved medicines: do recent market removals mean there is a problem?
The agency's drug review procedures and postmarketing surveillance system after a drug has been marketed are currently adequate but must continually adjust to future challenges. Expand
Market structure and drug innovation.
The interplay between technological advances and regulatory policies and their likely impact on the dynamics of the pharmaceutical industry are explored. Expand
Financing of vaccines
The need to increase the financial assistance for vaccine development is discussed, which will provide the flexibility to gain support from new constituencies, to strengthen institutions, and to create adequately strong budgetary commitments. Expand